Catalyze Capital invests in Neuro Event Labs
18 February 2025 – Catalyze Capital is happy to announce its investment in Neuro Event Labs Oy, as part of a €2 million investment round led by Hadean Ventures that will accelerate the commercial expansion of an AI-powered seizure detection device for epilepsy.
The proceeds will support commercial expansion in Europe as well as entry into the US market for its lead product Nelli®. With over 65 million patients suffering worldwide, epilepsy is one of the most common neurological diseases. The majority of these patients could become seizure-free with appropriate treatment following a proper diagnosis, however clear characterisation of the disease remains challenging and results in high misdiagnosis rates.
Neuro Event Labs Oy, based in Tampere, Finland, is a health technology company dedicated to AI motion diagnostics in Neurology, developing products that improve diagnosis, and thereby treatment, of neurological conditions. The lead product Nelli® is an AI-powered diagnostics and monitoring device for epilepsy, providing doctors with high-quality data of seizures based on video and audio recordings that can be collected in either the patient’s home or in a hospital environment.
Nelli® unlocks objective, accurate detection and characterisation of seizures in a cost-effective and patient-convenient manner. This enables the best possible treatment for epilepsy patients, significantly increasing the chance of becoming seizure-free.
“The positive impact this has on the daily lives of these patients is invaluable, while at the same time Nelli® also decreases the costs of care for epilepsy patients. Therefore, Catalyze Capital is excited to join the existing investors of Neuro Event Labs to further accelerate the growth and commercial roll-out of Nelli®.” says Benjamin Sieters, Investment Director at Catalyze Capital.
Looking for support?
How can we help you on your innovation journey? Contact our experts today.
